Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment

IMPORTANCE: Patients with amnestic mild cognitive impairment (aMCI) may progress to clinical Alzheimer disease (AD), remain stable, or revert to normal. Earlier progression to AD among patients who were β-amyloid positive vs those who were β-amyloid negative has been previously observed. Current res...

詳細記述

保存先:
書誌詳細
出版年:JAMA Neurol
主要な著者: Wolk, David A., Sadowsky, Carl, Safirstein, Beth, Rinne, Juha O., Duara, Ranjan, Perry, Richard, Agronin, Marc, Gamez, Jose, Shi, Jiong, Ivanoiu, Adrian, Minthon, Lennart, Walker, Zuzana, Hasselbalch, Steen, Holmes, Clive, Sabbagh, Marwan, Albert, Marilyn, Fleisher, Adam, Loughlin, Paul, Triau, Eric, Frey, Kirk, Høgh, Peter, Bozoki, Andrea, Bullock, Roger, Salmon, Eric, Farrar, Gillian, Buckley, Christopher J., Zanette, Michelle, Sherwin, Paul F., Cherubini, Andrea, Inglis, Fraser
フォーマット: Artigo
言語:Inglês
出版事項: American Medical Association 2018
主題:
Original Investigation
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143120/
https://ncbi.nlm.nih.gov/pubmed/29799984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2018.0894
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料